- Home
- TBPH vs TLRY Comparison
TBPH vs TLRY Comparison
Compare TBPH & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBPH | TLRY |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 688.9M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TBPH | TLRY |
|---|---|---|
| Price | $16.34 | $5.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $18.40 | ★ $72.33 |
| AVG Volume (30 Days) | 282.6K | ★ 5.7M |
| Earning Date | 05-04-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $8.79 |
| Revenue Next Year | N/A | $19.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.10 | $0.36 |
| 52 Week High | $21.03 | $15.70 |
Technical Indicators
Market Signals| Indicator | TBPH | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 36.07 |
| Support Level | $16.14 | $1.12 |
| Resistance Level | $17.21 | $7.01 |
| Average True Range (ATR) | 0.38 | 0.21 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 29.31 | 23.88 |
Price Performance
Historical ComparisonAbout TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.